Ultragenyx Pharmaceutical (RARE)
(Real Time Quote from BATS)
$58.77 USD
+1.07 (1.85%)
Updated Sep 19, 2024 03:44 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Ultragenyx (RARE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$90.86 | $140.00 | $46.00 | 57.47% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Ultragenyx comes to $90.86. The forecasts range from a low of $46.00 to a high of $140.00. The average price target represents an increase of 57.47% from the last closing price of $57.70.
Analyst Price Targets (21)
Broker Rating
Ultragenyx currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90.48% and 4.76% of all recommendations. A month ago, Strong Buy made up 90.48%, while Buy represented 4.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 19 | 19 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
8/2/2024 | Wells Fargo Securities | Tiago Fauth | Strong Buy | Strong Buy |
8/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
7/22/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
7/18/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
7/18/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
6/6/2024 | Goldman Sachs | Salveen Richter | Hold | Strong Buy |
5/31/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
5/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
5/3/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
4/22/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
3/15/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
2/16/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 21 |
Average Target Price | $90.86 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -1.42 |
RARE FAQs
Ultragenyx Pharmaceutical Inc. (RARE) currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms.
The average price target for Ultragenyx Pharmaceutical Inc. (RARE) is $90.86. The current on short-term price targets is based on 12 reports.
The forecasts for Ultragenyx Pharmaceutical Inc. (RARE) range from a low of $46 to a high of $140. The average price target represents a increase of $57.47 from the last closing price of $57.70.
The current UPSIDE for Ultragenyx Pharmaceutical Inc. (RARE) is 57.47%
Based on short-term price targets offered by 21 analysts, the average price target for Ultragenyx comes to $90.86. The forecasts range from a low of $46.00 to a high of $140.00. The average price target represents an increase of 57.47% from the last closing price of $57.70.